Enabling Intractable Assays
Providing mass spectrometry-based native detection technologies for the quantitation of difficult targets in complex matrixes.
Our broad variety of high-throughput and traditional platforms provide clients with a
competitive edge by decreasing sample processing time for unparalleled throughput.
With 50 years combined experience, our scientists have screened tens of millions of test compounds and drugs for clients in the fields of pharma, biopharma, biotech, gene therapy, and toxicology; taking numerous targets from assay design, through lead discovery, into drug development and even the clinic.
Pure Honey Technologies offers assay development, HTS screening, secondary screening, and in-life sample services. Once a target is selected, we can develop and optimize proprietary native detection screening assays; support large scale HTS primary screens; perform follow-up retests, IC50 determinations, binding affinity measurements, and specificity screening; and even help with pK/pD analysis.
By facilitating the screening of intractable assays, PureHoney Technologies provides drug discovery teams with an important competitive advantage in the search for new lead candidates.
Learn more about Pure Honey Technologies through the following downloadable brochures:
Our in-house technoloigy is here to provide you with speedy results, accurate analysis, and expandable project scope. Get in touch with us to explore your possibilities.
Early Compound Screening
Rare Disease Research
Affinity Selection (AS-MS)
This is just the beginning of our capabilities.
Get in touch to explore your project ideas with us.